文献速递艾滋病与性传播感染

含马拉维若方案预防MSM人群HIV感染的2期安全性研究

Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305).
PubMed 文献 · J Infect Dis · 2017-01-01

这项2期48周研究比较马拉维若单用、马拉维若联合恩曲他滨、马拉维若联合替诺福韦二吡呋酯及替诺福韦二吡呋酯联合恩曲他滨四种方案在406名HIV阴性男男性行为者中的安全性和耐受性。含马拉维若方案安全且耐受良好,停药率和3-4级不良事件率无组间差异,但研究未针对有效性设计把握度。

要点

  • 含马拉维若方案与TDF+FTC相比安全且耐受良好
  • 各方案停药率和3-4级不良事件率无显著差异
  • 5例HIV感染中4例为马拉维若单用,药物浓度缺失或低

核心结论

  • 含马拉维若方案与TDF+FTC相比安全且耐受良好
  • 本研究未针对有效性设计把握度
  • 含马拉维若方案可能值得进一步研究用于暴露前预防

研究设计与样本

  • 2期48周安全性/耐受性研究,比较4种方案:马拉维若单用、马拉维若联合恩曲他滨、马拉维若联合替诺福韦二吡呋酯、替诺福韦二吡呋酯联合恩曲他滨
  • 纳入406名HIV阴性男性和跨性别女性,报告90天内与至少1名HIV感染或血清状态不明的男性发生无套肛交
  • 分析采用意向性治疗

主要发现

  • 406名参与者中84%完成随访,7%提前停止,9%失访,9%提前终止方案
  • 终止方案人数和至终止时间在各方案间无差异(P = .60)
  • 3-4级不良事件率在各方案间无差异(P = .37)
  • 随机选取的子集中77%在48周时药物浓度可检测
  • 5名参与者感染HIV(4例马拉维若单用,1例马拉维若联合替诺福韦二吡呋酯;总体年化发病率1.4% [95% CI, .5%-3.3%],各方案间无差异;P = .32);2例每次访视药物浓度均不可检测,2例在血清转换访视时浓度低,1例浓度多变

临床怎么用

  • 含马拉维若方案安全性良好,但本研究未针对有效性设计把握度,不能据此推荐用于暴露前预防
  • 感染HIV者中药物浓度缺失、低或多变,提示依从性与预防效果相关

局限性

  • 本研究未针对有效性设计把握度

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Maraviroc (MVC) is a candidate for human immunodeficiency virus (HIV) pre-exposure prophylaxis. METHODS: Phase 2 48-week safety/tolerability study was conducted, comparing 4 regimens: MVC alone, MVC plus emtricitabine (FTC), MVC plus tenofovir disoproxil fumarate (TDF), and TDF plus FTC. Eligible participants were HIV-uninfected men and transgender women reporting condomless anal intercourse with ≥1 HIV-infected or unknown-serostatus man within 90 days. At each visit, assessments, laboratory testing, and counseling were done. Analyses were intention to treat. RESULTS: Among 406 participants, 84% completed follow-up, 7% stopped early, and 9% were lost to follow-up; 9% discontinued their regimen early. The number discontinuing and the time to discontinuation did not differ among study regimens (P = .60). Rates of grade 3-4 adverse events did not differ among regimens (P = .37). In a randomly selected subset, 77% demonstrated detectable drug concentrations at week 48. Five participants acquired HIV infection (4 MVC alone, 1 MVC + TDF; overall annualized incidence, 1.4% [95% confidence interval, .5%-3.3%], without differences by regimen; P = .32); 2 had undetectable drug concentrations at every visit, 2 had low concentrations at the seroconversion visit, and 1 had variable concentrations. CONCLUSIONS: MVC-containing regimens were safe and well tolerated compared with TDF + FTC; this study was not powered for efficacy. Among those acquiring HIV infection, drug concentrations were absent, low, or variable. MVC-containing regimens may warrant further study for pre-exposure prophylaxis. CLINICAL TRIALS REGISTRATION: NCT01505114.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Gulick RM, Wilkin TJ, Chen YQ, et al. Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305). J Infect Dis. 2017. PMID: 27811319. doi:10.1093/infdis/jiw525

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。